144 related articles for article (PubMed ID: 26554657)
21. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
22. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
23. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
24. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
25. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
Powell MA; Mutch DG; Rader JS; Herzog TJ; Huang TH; Goodfellow PJ
Cancer; 2002 Jun; 94(11):2941-52. PubMed ID: 12115383
[TBL] [Abstract][Full Text] [Related]
26. SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas.
Kihara A; Wakana K; Kubota T; Kitagawa M
Histopathology; 2016 Sep; 69(3):374-82. PubMed ID: 27003026
[TBL] [Abstract][Full Text] [Related]
27. [Impact of surgical resection extent on the prognosis of clinical stage I endometrial carcinoma].
Yan X; Gao YN; Jiang GQ; Gao M; An N
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):208-12. PubMed ID: 19615262
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
29. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
30. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
31. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma.
Huang JX; Chen WC; Lin M; Zhang YL; Li FY; Song ZX; Xiao W; Chen P; Qian RY; Salminen E; Yu H
Dis Esophagus; 2012 Feb; 25(2):121-9. PubMed ID: 21762277
[TBL] [Abstract][Full Text] [Related]
33. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
35. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
36. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
38. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
40. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis.
Todo Y; Kato H; Kaneuchi M; Watari H; Takeda M; Sakuragi N
Lancet; 2010 Apr; 375(9721):1165-72. PubMed ID: 20188410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
